Evidence map›Paper›PMID 28124442›Full record

SynthesisInternational journal of cancer2017

Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): A systematic review.

Sarah R Hoffman, Tam Le, Alexandre Lockhart, Ayodeji Sanusi, Leila Dal Santo, Meagan Davis, Dana A McKinney, Meagan Brown, Charles Poole, Corinne Willame and 1 more

Registry-linked trialOpen access · bronzeAbstract readSystematic Review
In one paragraph

Synthesis in International journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06137950 (Interferon Alpha Therapy for Cervical CIN I and HPV Infection), which is not on this map. Cited by 78 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed, 3 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06137950 phase1completednot on this mapstarted 2023, after this paper: background citation

Interferon Alpha Therapy for Cervical CIN I and HPV Infection

TypeinterventionalSponsorMongolian National University of Medical SciencesRan2023 to 2025Enrolled60ConditionsCervical Dysplasia, HPV InfectionArmsgel Interferon arm, gel Interferon and interferon suppository arm
3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 3 syntheses or guidelines pooled it, 154 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. REBACINWorld journal of surgical oncology · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

Sarah R HoffmanDepartment of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC.ORCID 0000-0001-5629-160X
Tam LeUNC School of Medicine, Chapel Hill, NC.
Alexandre LockhartDepartment of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC.
Ayodeji SanusiDepartment of Maternal and Child Health, UNC Gillings School of Global Public Health, Chapel Hill, NC.
Leila Dal SantoDepartment of Maternal and Child Health, UNC Gillings School of Global Public Health, Chapel Hill, NC.
Meagan DavisDepartment of Health Behavior, UNC Gillings School of Global Public Health, Chapel Hill, NC.
Dana A McKinneyDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Meagan BrownDepartment of Health Behavior, UNC Gillings School of Global Public Health, Chapel Hill, NC.
Charles PooleDepartment of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC.
Corinne WillameBusiness & Decision Life Science on behalf of GlaxoSmithKline Vaccines, Wavre, Belgium.
Jennifer S SmithDepartment of Epidemiology, UNC Gillings School of Global Public Health, Chapel Hill, NC.
University of North Carolina Health Care · USDepartment of Health · ZAEmory University · USGlaxoSmithKline (Belgium) · BEUniversity of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
NCI NIH HHS P30 CA016086
6 · The paper itself

Abstract

A systematic review of the literature was conducted to determine the estimates of and definitions for human papillomavirus (HPV) persistence in women following treatment of cervical intra-epithelial neoplasia (CIN). A total of 45 studies presented data on post-treatment HPV persistence among 6,106 women. Most studies assessed HPV persistence after loop excision (42%), followed by conization (7%), cryotherapy (11%), laser treatment (4%), interferon-alpha, therapeutic vaccination, and photodynamic therapy (2% each) and mixed treatment (38%). Baseline HPV testing was conducted before or at treatment for most studies (96%). Follow-up HPV testing ranged from 1.5 to 80 months after baseline. Median HPV persistence tended to decrease with increasing follow-up time, declining from 27% at 3 months after treatment to 21% at 6 months, 15% at 12 months, and 10% at 24 months. Post-treatment HPV persistence estimates varied widely and were influenced by patient age, HPV-type, detection method, treatment method, and minimum HPV post-treatment testing interval. Loop excision and conization appeared to outperform cryotherapy procedures in terms of their ability to clear HPV infection. This systematic review provides evidence for the substantial heterogeneity in post-treatment HPV DNA testing practices and persistence estimates.

Indexed as

FemaleHuman Papillomavirus DNA TestsHumansNeoplasm Recurrence, LocalPapillomaviridaePapillomavirus InfectionsPhotochemotherapyRisk FactorsUterine Cervical Dysplasiacervical cancerCINHPVHPV persistencehuman papillomavirus

Identifiers

PMID28124442
PMCPMC5606195
OpenAlexW2580399831

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.